Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

NoStop: Personalised Small Molecule Gene Therapy

Objective

Premature termination codons (PTCs) account for 10–20% of genetic disease cases and represent a major mechanism of tumor suppressor gene inactivation. A therapeutic approach capable of reverting PTCs into sense codons would have broad applicability, benefiting millions of patients across diverse genetic disorders and cancers. Readthrough therapy offers this potential; however, its clinical impact has so far been limited by disappointing trial outcomes.
Using a combination of in-house–developed high-throughput human readthrough assays and machine learning, we recently demonstrated that a key factor underlying this limited success is the strong sequence specificity of readthrough drugs, which varies markedly among compounds. With the NoStop platform, our goal is to build on this validated technology to transform the readthrough therapy field by systematically generating comprehensive PTC-specificity maps for all known readthrough compounds, while simultaneously establishing a sequence-tailored high-throughput drug discovery pipeline to identify novel proprietary readthrough drugs. If successful, NoStop will generate invaluable data to enable the transition of readthrough therapy from a one-size-fits-all approach to a personalized medicine paradigm.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

FUNDACIO CENTRE DE REGULACIO GENOMICA
Net EU contribution
€ 107 000,00
Address
CARRER DOCTOR AIGUADER 88
08003 Barcelona
Spain
Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (2)